Staff Profile
Publications
- Coxon C, Anscombe E, Harnor S, Martin M, Carbain B, Golding B, Hardcastle I, Harlow L, Korolchuk S, Matheson C, Newell D, Noble M, Sivaprakasam M, Tudhope SJ, Turner D, Wang L, Wedge SR, Wong C, Griffin R, Endicott J, Cano C. Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry 2017, 60, 1746-1767.
- Al-Oanzi ZH, Fountana S, Moonira T, Tudhope SJ, Petrie JL, Alshawi A, Patman G, Arden C, Reeves HL, Agius L. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. Diabetes, Obesity and Metabolism 2017, 19(8), 1078-1087.
- Barrow TM, Woodhouse L, Junge G, Tudhope SJ, Behardien C, Wallis JP, Marr HJ, Marshall SR, Bown N, Willmore E, Strathdee G. The Role of HOXA4 in Chronic Lymphocytic Leukaemia Progression and Response to Therapy. In: American Society of Hematology (ASH) 58th Annual Meeting & Exposition. 2016, San Diego, CA (USA): American Society of Hematology.
- Willmore E, Gardner A, Tudhope S, Murtani B, Caffry J, Mulligan E, Hunter J, Wallis J, Marr H, Beretta G, Breen D, Paul A, Edwards D, Young L, Suckling C, Plevin R, Boyd M, Mackay S, Perkins N. Novel small molecule IKK alpha inhibitors inhibit non- canonical NF-kappa B signaling and survival of primary CLL cells. In: XVI International Workshop on Chronic Lymphocytic Leukemia. 2015, Sydney, Australia: Taylor & Francis.
- Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patternson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia. Oncotarget 2015, 6(41), 43978-43991.
- Marr H, Gaughan L, Tudhope SJ, Allan JM. Regulation of CD38 in IRF4 in Chronic Lymphocytic Leukaemia. In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Ferrata Storti Foundation.
- Tudhope S, Zhao Y, Wittner A, Wilmore E, Bertoli A, Adhikari S, Harnor SJ, Del Bello F, Piergentili A, Lunec J, Hardcastle IR, Griffin RJ, Golding BR, Cano C, Newell DR, Wedge SR. Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
- Iannetti A, Ledoux AC, Tudhope SJ, Sellier H, Zhao B, Mowla S, Moore A, Hummerich H, Gewurz BE, Cockell SJ, Jat PS, Willmore E, Perkins ND. Regulation of p53 and Rb Links the Alternative NF-kappaB Pathway to EZH2 Expression and Cell Senescence. PLoS Genetics 2014, 10(9), e1004642.
- Bertoli A, Adhikari S, Harnor SJ, Zhao Y, Lunec J, Wedge SR, Tudhope S, Wittner A, Golding BT, Hardcastle IR, Cano C, Newell DR, Griffin RJ. Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction. In: 247th ACS National Meeting and Exposition. 2014, Dallas, TX, USA: American Chemical Society.
- Petrie JL, Al-Oanzi ZH, Arden C, Tudhope SJ, Mann J, Kieswich J, Yaqoob MM, Towle HC, Agius L. Glucose induces protein targeting to glycogen in hepatocytes by fructose 2,6-bisphosphate-mediated recruitment of MondoA to the promoter. Molecular and Cellular Biology 2013, 33(4), 725-738.
- Tudhope SJ, Wang CC, Petrie JL, Potts L, Malcomson F, Kieswich J, Yaqoob MM, Arden C, Hampson LJ, Agius L. A Novel Mechanism for Regulating Hepatic Glycogen Synthesis Involving Serotonin and Cyclin-Dependent Kinase-5. Diabetes 2012, 61(1), 49-60.
- Ugarte-Gil LJ, Mould E, Tudhope S, Prado MA, Iglesias-Rodriguez J, Willmore E, Lazo PS. DNA-PK inhibitors NU7026 and NU7441 as enhancers of topoisomerase II poisons cytotoxicity. In: FEBS JOURNAL. 2012, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.
- Arden C, Tudhope SJ, Petrie JL, Al-Oanzi ZH, Cullen KS, Lange AJ, Towle HC, Agius L. Fructose 2,6-bisphosphate is essential for glucose-regulated genetranscription of glucose-6-phosphatase and other ChREBP target genes inhepatocytes. Biochemical Journal 2012, 443(1), 111-123.
- Tudhope SJ, Mulligan EA, Hunter JE, Summerfield GP, Marshall S, Wallis J, Marr H, Evans P, Lowe C, Durkacz BW, Zhang J, Meshulam J, Bobb K, Willmore E. P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
- Al-Oanzi ZH, Petrie JL, Tudhope S, Arden C, Agius L. The insulin-independent glucose-induction of the hepatic gluconeogenic enzyme glucose 6-phosphatase involves distinct metabolic pathways and transcription factors. In: 48th General Assembly of the European Association for the Study of Diabetes. 2012, Berlin, Germany: Springer.
- Arden C, Petrie JL, Tudhope SJ, Al-Oanzi Z, Claydon AJ, Beynon RJ, Towle HC, Agius L. Elevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasis. Diabetes 2011, 60(12), 3110-3120.
- Ng WF, Tudhope SJ, von Delwig A, Lilic D. Invariant natural killer T (iNKT) cell deficiency in chronic mucocutaneous candidiasis - A consequence or a cause?. Immunology Letters 2011, 135(1-2), 180-183.